The emergence of multi-drug resistant Acinetobacter strains has created an urgent medical need for the development of novel therapeutics targeting this pathogen. Currently, treatment options are extremely limited due to multidrug resistance. The global Acinetobacter pneumonia therapeutics market is estimated to be valued at US$ 614.9 million in 2024 and is expected to exhibit a CAGR of 5.8%...
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
urdu